Reparo de defeitos ósseos críticos usando hidroxiapatita sintética ou bovina com ou sem fração mononuclear da medula óssea: análise histomorfométrica e imuno-histoquímica

• Autor(a) principal: Pires, Jorge Luís da Silva
• Data de Publicação: 2020
• Outros Autores: [e-mail]
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/19305
• topic: Osseointegration; Bone regeneration; Mononuclear fraction of the bone marrow; Critical bone defects; Osseointegração; Regeneração óssea; Fração mononuclear da medula óssea; Defeito ósseo crítico; CIENCIAS DA SAUDE::ODONTOLOGIA

The present study aimed to evaluate the bone regeneration of critical bone defects in the calvaria of rats using xenogenous grafts, Bio-Oss Small (Bio-Oss® Geistlich Pharma AG, Wolhusen, Switzerland) and synthetic hypooxypatite, (Alobone poros Osseocon Biomateriais Ltda., Rio de Janeiro / RJ, Brazil) pure or enriched with the medullary mononuclear fraction of stem cells, in the material and methods: forty young adult male rats, Sprague Dawley, were used, with twelve weeks distributed in five groups with eight animals, being thus named: control group, group 1, group 2, group 3, and group 4. In addition to the forty young adult rats, eight more animals were used as bone marrow donors. The Five groups were submitted to critical size bone defects with 8 (eight) millimeter diameter trephine, in the temporoparietal region. In the control group there was no biomaterial placement, in group 1 the critical size bone defects were filled with synthetic hydroxyapatite, 0,10 grams, (Alobone poros Osseocon Biomateriais Ltda., Rio de Janeiro / RJ, Brazil), in group 2 they were filled with bovine hydroxyapatite,0,10gramas, Bio-Oss Small (Bio-Oss® Geistlich Pharma AG, Wolhusen, Switzerland), in group 3 the critical size bone defects were filled with synthetic hydroxyapatite,0,10 grams, (Alobone poros Osseocon Biomateriais Ltda., Rio de Janeiro / RJ, Brazil) enriched with 300 µl of BMMF containing 1x106 cells, obtained from bone marrow donors animals, and in group 4 the critical size bone defects were filled with bovine hydroxyapatite, 0,10 grams Bio-Oss Small (Bio-Oss® Geistlich Pharma AG, Wolhusen, Switzerland) enriched with 300 µl of BMMF containing 1x106 cells, obtained from bone marrow donors animals. After eight weeks, all five of animals were euthanized by Pentobarbital anesthetic overdose (180 mg / kg intraperitoneal). The groups were submitted to histomorphometric analysis, using Masson's trichrome Stain, and immunohistochemical techniques of VEGF and Osteopontin. There was no statistically significant difference among groups 1, 2, 3 and 4, but it did exist with the control group and the other groups that received treatment for the regeneration of critical bone defects.